The "Molecular Mechanisms in Alzheimer’s" track delves into the fundamental biological processes driving the development and progression of Alzheimer’s disease. This includes an exploration of protein aggregation, cellular dysfunction, neuro inflammation, and the interplay of genetic and environmental factors. By unraveling these mechanisms, researchers aim to identify therapeutic targets and develop interventions that can halt or reverse disease progression

Track 1:1 Protein Misfolding and Aggregation

Track 1:2 Synaptic Dysfunction and Neurodegeneration

Track 1:3 Role of Mitochondrial Dysfunction and Oxidative Stress

Track 1:4 Neuro inflammation and Glial Cell Activation  

Track 1:5 Cellular Waste Management and Autophagy

Biomarkers are measurable indicators of biological processes, providing crucial insights into Alzheimer’s disease (AD) for early detection, tracking progression, and evaluating therapeutic efficacy. The search for reliable biomarkers focuses on detecting Alzheimer’s before significant cognitive decline occurs, enabling earlier interventions and improved outcomes. Current advancements include imaging techniques, bio fluid assays, and genetic markers. These tools are revolutionizing clinical practices, offering non-invasive, accurate methods to diagnose Alzheimer’s and predict its progression.

Track 2:1 Neuroimaging Biomarkers

Track 2:2 Fluid Biomarkers

Track 2:3 Genetic and Epigenetic Biomarkers

Track 2:4 Metabolic and Proteomic Biomarkers

Track 2:5 Multimodal Biomarker Approaches

Neuroimaging is revolutionizing our understanding of Alzheimer’s disease by providing detailed insights into brain structure, function, and pathology. Advances in imaging technologies have enabled early diagnosis, tracking of disease progression, and evaluation of treatment efficacy. This track will explore the latest breakthroughs in neuroimaging techniques, their applications in clinical and research settings, and their potential to transform Alzheimer’s care.

Track 3:1 Advanced MRI Techniques in Alzheimer’s Research

Track 3:2 Positron Emission Tomography Imaging for Alzheimer’s Pathology

Track 3:3 Multimodal Imaging Approaches

Track 3:4 Imaging for Early Detection and Risk Prediction

Track 3:5 Artificial Intelligence in Neuroimaging

 Advances in Alzheimer’s Therapies focuses on the latest breakthroughs in therapeutic approaches for Alzheimer’s disease. With a growing understanding of the disease’s underlying mechanisms, researchers and clinicians are making significant strides in developing targeted treatments. This includes pharmacological innovations, immunotherapies, gene-based approaches, and non-pharmacological interventions aimed at slowing disease progression, managing symptoms, and improving quality of life for patients and caregivers.

Track 4:1 Immunotherapy and Monoclonal Antibodies

Track 4:2 Gene Therapy and RNA-Based Treatments

Track 4:3 Neuroprotective and Neurorestorative Agents

Track 4:4 Combination Therapies

Track 4:5 Non-Pharmacological Therapeutic Innovations

This track focuses on the critical role that lifestyle choices play in reducing the risk of developing Alzheimer’s disease and dementia. It highlights research and strategies that emphasize proactive approaches to promote cognitive health and overall well-being. By investigating the impact of diet, physical activity, social engagement, and other lifestyle factors, this track aims to provide a comprehensive view of prevention strategies that can be adopted at individual and community levels.

Track 5:1 Nutrition and Cognitive Health

Track 5:2 Physical Activity and Brain Function

Track 5:3 Social Engagement and Cognitive Resilience

Track 5:4 Mental Stimulation and Cognitive Training

Track 5:5 Sleep and Cognitive Function

The application of Artificial Intelligence (AI) in dementia research is transforming the way we understand, diagnose, and manage Alzheimer’s and other forms of dementia. With the ability to process vast amounts of data and recognize complex patterns, AI is accelerating advancements in early diagnosis, personalized care, and predictive analytics. This track will explore how AI technologies, such as machine learning, deep learning, and natural language processing, are being harnessed to improve clinical outcomes, enhance patient monitoring, and support healthcare professionals.

Track 6:1 AI-Powered Diagnostic Tools

Track 6:2 Predictive Analytics in Disease Progression

Track 6:3 Natural Language Processing for Cognitive Assessment

Track 6:4 Wearable Tech and AI for Patient Monitoring

Track 6:5 Ethics and Data Privacy in AI Research

Precision medicine represents a paradigm shift in the way we approach treatment and care for Alzheimer’s and other dementias. Unlike one-size-fits-all methods, precision medicine tailors interventions based on an individual's genetic, environmental, and lifestyle factors. By understanding the unique profile of each patient, this approach aims to optimize treatment outcomes and minimize side effects, ultimately leading to better management of the disease and improved patient care. This track will explore current advancements, challenges, and the future potential of precision medicine in dementia research and clinical practice.

Track 7:1 Genomic Insights for Personalized Care

Track 7:2 Pharmacogenomics and Medication Management

Track 7:3 Biomarker Discovery and Patient Stratification

Track 7:4 Integrating Lifestyle and Environmental Factors

Track 7:5 Challenges and Future Directions in Precision Dementia Care

Neuroinflammation is increasingly recognized as a crucial component in the pathogenesis of Alzheimer’s disease and other forms of dementia. The immune system's response within the central nervous system (CNS) plays a significant role in either protecting or damaging brain cells. Chronic neuroinflammation can contribute to the progression of neurodegenerative diseases, promoting damage to neurons and supporting the toxic accumulation of proteins such as amyloid-beta and tau. Understanding the mechanisms of neuroinflammation and immune pathways is essential for identifying novel therapeutic targets and strategies to slow or halt disease progression.

Track 8:1 Microglial Activation and Neurodegeneration

Track 8:2 Astrocyte Response and Brain Health

Track 8:3 Systemic Inflammation and Blood-Brain Barrier Integrity

Track 8:4 Inflammatory Cytokines and Disease Progression

Track 8:5 Therapeutic Approaches to Modulate Neuroinflammation

Genetics and Epigenetics of Alzheimer’s will explore the profound role that genetics and epigenetic mechanisms play in the development, progression, and potential prevention of Alzheimer’s disease. Researchers and scientists are uncovering the complexities of how genetic predispositions, mutations, and environmental influences shape brain health. Understanding these molecular and hereditary factors can inform personalized medicine approaches, contribute to earlier diagnoses, and identify targeted interventions for slowing or preventing the disease.
 

Track 9:1 Genetic Risk Factors and Alzheimer’s Onset

Track 9:2 Epigenetic Modifications and Cognitive Decline

Track 9:3 Molecular Pathways in Alzheimer’s Genetics

Track 9:4 Genetic Screening and Early Diagnosis

Track 9:5 Epigenetic Biomarkers for Early Detection

Vascular Dementia Insights delves into vascular dementia, the second most common form of dementia after Alzheimer's disease. It is caused by conditions that damage blood vessels in the brain, leading to reduced blood flow and cognitive impairment. Vascular dementia can result from stroke, chronic hypertension, atherosclerosis, or other conditions that compromise vascular health. Understanding the underlying mechanisms, risk factors, diagnostic methods, and treatment strategies for vascular dementia is essential for improving patient outcomes. This track highlights the intersection of cardiovascular health and brain function, providing insights into prevention, diagnosis, and management.
 

Track 10:1 Pathophysiology and Mechanisms of Vascular Dementia

Track 10:2 Risk Factors and Prevention Strategies

Track 10:3 Diagnostic Tools and Imaging Techniques

Track 10:4 Management and Treatment Approaches

Track 10:5 Differential Diagnosis and Co-Existing Dementias

Rare dementia subtypes represent a significant and often under-researched area of Alzheimer's and dementia studies. While Alzheimer's disease and vascular dementia are more widely recognized, there are numerous rare subtypes, each with unique clinical, genetic, and pathological features. Understanding these subtypes is essential for accurate diagnosis, tailored treatment plans, and advancements in care strategies. This track aims to shed light on the clinical presentations, research, and management approaches for rare forms of dementia, contributing to the broader understanding of cognitive disorders and improving patient outcomes.

Track 11:1 Frontotemporal Dementia

Track 11:2 Lewy Body Dementia

Track 11:3 Primary Progressive Aphasia

Track 11:4 Posterior Cortical Atrophy

Track 11:5 Corticobasal Degeneration

Neuroplasticity refers to the brain’s ability to reorganize itself by forming new neural connections throughout life, enabling adaptation to new experiences and recovery from damage. In the context of Alzheimer's disease, understanding neuroplasticity is crucial for developing interventions that can enhance cognitive function and delay disease progression. Resilience, on the other hand, is the brain's capacity to withstand or recover from damage. Studying how neuroplasticity and resilience contribute to cognitive health offers hope for strategies that maintain or improve brain function in the face of neurodegenerative diseases.

Track 12:1 Mechanisms of Neuroplasticity in Aging Brains

Track 12:2 Lifestyle Factors Promoting Brain Resilience

Track 12:3 Neuroplasticity and Cognitive Training Programs

Track 12:4 Role of Stress and Neuroinflammation in Brain Resilience

Track 12:5 Biomarkers for Assessing Neuroplasticity and Resilience

Public Health and Dementia Prevention examines the broad public health strategies and initiatives aimed at preventing dementia and promoting brain health across populations. It underscores the importance of community awareness, health education, and policy development in reducing the incidence and impact of dementia. Effective prevention involves a combination of lifestyle modifications, early detection, access to healthcare, and socioeconomic support systems. This track will explore evidence-based approaches, current public health campaigns, and global efforts aimed at building dementia-friendly communities and environments.

Track 13:1 Community-Based Dementia Prevention Programs

Track 13:2 Role of Diet and Nutrition in Dementia Prevention

Track 13:3 Physical Activity and Cognitive Function

Track 13:4 Social Determinants of Dementia Risk

Track 13:5 Public Health Campaigns and Awareness Initiatives

Assistive technology (AT) encompasses a wide range of tools and devices designed to enhance the quality of life for individuals living with Alzheimer’s and dementia, as well as to support caregivers in their roles. These technologies help maintain independence, improve safety, facilitate communication, and provide caregivers with valuable tools for monitoring and assistance. The advancement of AT in recent years has led to innovative solutions that leverage AI, sensors, wearable devices, and smart home technology, revolutionizing how care is provided and managed.

Track 14:1 Smart Home Solutions for Safety and Independence

Track 14:2 Wearable Technology for Monitoring and Health Tracking

Track 14:3 Assistive Communication Tools

Track 14:4 AI-Powered Cognitive Support Tools

Track 14:5 Remote Care and Tele health Solutions

Caregiver Resources and Support is dedicated to addressing the needs of caregivers—both professional and family—who play an essential role in the lives of individuals with Alzheimer’s and dementia. Providing effective support, tools, and resources for caregivers is crucial to ensure high-quality care, prevent caregiver burnout, and promote the well-being of both caregivers and patients. This track will cover the challenges caregivers face, innovative solutions for providing support, and strategies to enhance caregiving experiences and outcomes.

Track 15:1 Training and Education Programs for Caregivers

Track 15:2 Technology and Tools for Enhanced Care

Track 15:3 Emotional and Psychological Support for Caregivers

Track 15:4 Financial and Legal Resources for Caregiving Families

Track 15:5 Community-Based Support Programs

This track focuses on the approaches and strategies for managing the non-cognitive symptoms of Alzheimer’s disease, which can significantly impact patients and caregivers. Behavioral symptoms, such as aggression, agitation, depression, and anxiety, are common as the disease progresses and can severely affect quality of life. Addressing these symptoms effectively requires a combination of pharmacological and non-pharmacological interventions. The goal is to improve patient well-being and support caregivers through evidence-based practices and innovative treatment approaches.

Track 16:1 Non-Pharmacological Interventions

Track 16:2 Pharmacological Treatment Approaches

Track 16:3 Caregiver Training and Support

Track 16:4 Impact of Environment and Routine on Behavior

Track 16:5 Technology-Assisted Behavioral Management

This track delves into the complex relationship between aging, Alzheimer’s disease, and other comorbid health conditions. Aging is the most significant risk factor for dementia, and many individuals with Alzheimer’s and related dementias also have other chronic conditions that impact their health, quality of life, and treatment outcomes. The interaction between these comorbidities and neurodegenerative diseases can complicate diagnosis, management, and care strategies, making it essential to understand the connections and develop comprehensive approaches for patient care.

Track 17:1 The Impact of Cardiovascular Health on Cognitive Decline

Track 17:2 Diabetes and Alzheimer’s Disease: A Dual Challenge

Track 17:3 Neurodegeneration and Metabolic Disorders

Track 17:4 The Role of Inflammation and Immune System Dysregulation

Track 17:5 Poly pharmacy and Its Effects on Cognitive Function

Dementia care presents significant challenges on a global scale due to its widespread impact and varying levels of resources and support across different regions. Factors such as aging populations, limited access to healthcare services, cultural differences in care practices, and economic disparities contribute to the complexity of managing dementia effectively worldwide. This track delves into the systemic issues that hinder dementia care, including policy, healthcare infrastructure, and social stigma, and seeks to identify collaborative strategies and solutions to ensure equitable, high-quality care for all individuals affected by dementia.

Track 18:1 Healthcare System Disparities in Dementia Care

Track 18:2 Cultural Perspectives and Stigma

Track 18:3 Workforce Training and Support

Track 18:4 Policy and Funding for Dementia Care

Track 18:5 Technological Innovations and Accessibility

Ethics and Policy in Alzheimer’s Care focuses on the ethical and policy-related challenges in the care, treatment, and management of individuals affected by Alzheimer’s disease. Addressing these issues is essential to create a dementia-friendly society that respects patient rights, ensures equitable access to care, and supports both caregivers and individuals with Alzheimer’s. Ethical considerations, including patient autonomy, informed consent, and end-of-life decisions, play a crucial role in care delivery and research. Meanwhile, policies shape the landscape of Alzheimer’s care through funding, public health strategies, and legislative measures. This track aims to foster discussions on best practices, innovative policies, and ethical principles that can drive better outcomes for patients and their families.

Track 19:1 Patient Autonomy and Informed Consent

Track 19:2 Legal and Rights Issues for Alzheimer’s Patients

Track 19:3 Access to Alzheimer’s Care and Equity

Track 19:4 End-of-Life Care and Ethical Dilemmas

Track 19:5 Policy Innovations and Dementia-Friendly Communities

The future of dementia research holds tremendous promise, with rapid advancements in technology, data analytics, and scientific understanding. This track focuses on the most promising areas and methodologies that will shape the next decade of research into Alzheimer’s disease and other dementias. It will explore innovative approaches to early detection, intervention, and treatment, as well as the integration of global perspectives in research initiatives. This track will emphasize the importance of interdisciplinary collaboration and the use of cutting-edge tools, such as artificial intelligence (AI) and advanced imaging technologies, to push the boundaries of what is possible in dementia science.

Track 20:1 Next-Generation Imaging and Diagnostic Tools

Track 20:2 AI and Machine Learning in Dementia Research

Track 20:3 Regenerative Medicine and Stem Cell Research

Track 20:4 Global Collaborative Research Initiatives

Track 20:5 Personalized and Precision Approaches in Dementia Care